Serotype/serogroup-specific antibiotic non-susceptibility of invasive and non-invasive Streptococcus pneumoniae, Switzerland, 2004 to 2014

Eurosurveillance

Volumn 21, Issue 21, 2016, Pages 1-10

  Hauser, C ^a,b   Kronenberg, A ^a,b   Allemann, A ^a,c   Muhlemann K ^a,b   Hilty, Markus ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; CEFTRIAXONE; COTRIMOXAZOLE; ERYTHROMYCIN; ETHYLHYDROCUPREINE; LEVOFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; ANTIINFECTIVE AGENT;

ACUTE OTITIS MEDIA; ADOLESCENT; ADULT; AGE; AGED; ANTIBIOTIC NON SUSCEPTIBILITY; ANTIBIOTIC RESISTANCE; ARTICLE; BILE; BLOOD; CEREBROSPINAL FLUID; CHILD; DRUG SENSITIVITY; GENDER; GEOGRAPHIC ORIGIN; HUMAN; JOINT; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PERITONEAL FLUID; PLEURA FLUID; PNEUMOCOCCAL INFECTION; PNEUMONIA; SENTINEL SURVEILLANCE; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; SWITZERLAND; AGE DISTRIBUTION; CLASSIFICATION; DISEASE OUTBREAKS; DRUG EFFECTS; FEMALE; INFANT; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PNEUMONIA, PNEUMOCOCCAL; PRESCHOOL CHILD; PREVALENCE; RISK FACTOR; SEX RATIO; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; PREVALENCE; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SEROGROUP; SEX DISTRIBUTION; STREPTOCOCCUS PNEUMONIAE; SWITZERLAND; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85015354603     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2016.21.21.30239     Document Type: Article

References (29)

1. Aebi C, Duppenthaler A. [Antimicrobial resistance--consequences for ambulatory treatment of infections in children]. Ther Umsch. 2002;59(1):46-50. German. DOI: 10.1024/0040-5930.59.1.46 PMID: 11851047
2. Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000;90(2):223-9. DOI: 10.2105/AJPH.90.2.223 PMID: 10667183
3. Schwaber MJ, De-Medina T, Carmeli Y. Epidemiological interpretation of antibiotic resistance studies-what are we missing?Nat Rev Microbiol. 2004;2(12):979-83. DOI: 10.1038/ nrmicro1047 PMID: 15550943
4. Meichtry J, Born R, Küffer M, Zwahlen M, Albrich WC, Brugger SD, et al. Serotype epidemiology of invasive pneumococcal disease in Swiss adults: a nationwide population-based study. Vaccine. 2014;32(40):5185-91. DOI: 10.1016/j. vaccine.2014.07.060 PMID: 25077419
5. Song JH, Dagan R, Klugman KP, Fritzell B. The relationship between pneumococcal serotypes and antibiotic resistance.Vaccine. 2012;30(17):2728-37. DOI: 10.1016/j. vaccine.2012.01.091 PMID: 22330126
6. Kronenberg A, Zucs P, Droz S, Mühlemann K. Distribution and invasiveness of Streptococcus pneumoniae serotypes in Switzerland, a country with low antibiotic selection pressure, from 2001 to 2004.J Clin Microbiol. 2006;44(6):2032-8. DOI: 10.1128/JCM.00275-06 PMID: 16757594
7. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.Clin Infect Dis. 2001;32(Suppl 2):S81-93.
8. Mühlemann K, Matter HC, Täuber MG, Bodmer T, Sentinel Working Group. Nationwide surveillance of nasopharyngeal Streptococcus pneumoniae isolates from children with respiratory infection, Switzerland, 1998-1999.J Infect Dis. 2003;187(4):589-96. DOI: 10.1086/367994 PMID: 12599075
9. Bundesamt für Gesundheit (BAG). Repräsentativität des Sentinella-Ärztekollektivs. [Representativeness of the collective of sentinel physicians]. BAG Bulletin. 2001;37(01):680. German. Available from: http://www.bag. admin.ch/dokumentation/publikationen/01435/01801/index.ht ml?lang=de&download=NHzLpZig7t,lnp6I0NTU042l2Z6ln1acy 4Zn4Z2qZpnO2Yuq2Z6gpJCEdX56fWym162dpYbUzd,Gpd6emK2 Oz9aGodetmqaN19XI2IdvoaCUZ,s-
10. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, twentysecond informational supplement. Document M100-S22. Wayne: CLSI; 2012
11. Goossens H, Ferech M, Vander Stichele R, Elseviers M, ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study.Lancet. 2005;365(9459):579-87. DOI: 10.1016/S0140-6736(05)70799-6 PMID: 15708101
12. Kempf M, Varon E, Lepoutre A, Gravet A, Baraduc R, Brun M, et al. Decline in antibiotic resistance and changes in the serotype distribution of Streptococcus pneumoniae isolates from children with acute otitis media; a 2001-2011 survey by the French Pneumococcal Network. Clin Microbiol Infect. 2015;21(1):35-42. DOI: 10.1016/j.cmi.2014.08.009 PMID: 25636925
13. Filippini M, Masiero G, Moschetti K. Socioeconomic determinants of regional differences in outpatient antibiotic consumption: evidence from Switzerland.Health Policy. 2006;78(1):77-92. DOI: 10.1016/j.healthpol.2005.09.009 PMID: 16290129
14. Imöhl M, Reinert RR, Mutscher C, van der Linden M. Macrolide susceptibility and serotype specific macrolide resistance of invasive isolates of Streptococcus pneumoniae in Germany from 1992 to 2008.BMC Microbiol. 2010;10(1):299. DOI: 10.1186/1471-2180-10-299 PMID: 21108778
15. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354(14):1455-63. DOI: 10.1056/NEJMoa051642 PMID: 16598044
16. Hackel M, Lascols C, Bouchillon S, Hilton B, Morgenstern D, Purdy J. Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations.Vaccine. 2013;31(42):4881-7. DOI: 10.1016/j. vaccine.2013.07.054 PMID: 23928466
17. Imöhl M, Reinert RR, van der Linden M. Serotype-specific penicillin resistance of Streptococcus pneumoniae in Germany from 1992 to 2008.Int J Med Microbiol. 2010;300(5):324-30. DOI: 10.1016/j.ijmm.2009.11.004 PMID: 20071233
18. Dagan R, Juergens C, Trammel J, Patterson S, Greenberg D, Givon-Lavi N, et al. Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibioticnonsusceptible Streptococcus pneumoniae. J Infect Dis. 2015;211(7):1144-53. DOI: 10.1093/infdis/jiu576 PMID: 25355940
19. Bundesamt für Gesundheit (BAG). Pneumokokken-Erkrankungen. [Pneumococcal diseases]. Bern: BAG; 2013. German. Available from: http://www.bag.admin.ch/themen/ medizin/00682/00684/01097/index.html?lang=it
20. Chiba N, Morozumi M, Shouji M, Wajima T, Iwata S, Ubukata K, et al. Changes in capsule and drug resistance of Pneumococci after introduction of PCV7, Japan, 2010-2013. Emerg Infect Dis. 2014;20(7):1132-9. DOI: 10.3201/eid2007.131485 PMID: 24960150
21. Regev-Yochay G, Paran Y, Bishara J, Oren I, Chowers M, Tziba Y, et al. Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: A nationwide surveillance study. Vaccine. 2015;33(9):1135-42. DOI: 10.1016/j. vaccine.2015.01.030 PMID: 25613717
22. Lambertsen LM, Harboe ZB, Konradsen HB, Christensen JJ, Hammerum AM. Non-invasive erythromycin-resistant pneumococcal isolates are more often non-susceptible to more antimicrobial agents than invasive isolates. Int J Antimicrob Agents. 2010;35(1):72-5. DOI: 10.1016/j. ijantimicag.2009.09.006 PMID: 19892529
23. Saha SK, Baqui AH, Darmstadt GL, Ruhulamin M, Hanif M, El Arifeen S, et al. Comparison of antibiotic resistance and serotype composition of carriage and invasive pneumococci among Bangladeshi children: implications for treatment policy and vaccine formulation. J Clin Microbiol. 2003;41(12):5582-7. DOI: 10.1128/JCM.41.12.5582-5587.2003 PMID: 14662944
24. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN, Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.J Antimicrob Chemother. 2003;52(2):229-46. DOI: 10.1093/jac/dkg321 PMID: 12865398
25. Beekmann SE, Heilmann KP, Richter SS, García-de-Lomas J, Doern GV, GRASP Study Group. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program.Int J Antimicrob Agents. 2005;25(2):148-56. DOI: 10.1016/j.ijantimicag.2004.09.016 PMID: 15664485
26. Pérez-Trallero E, Marimón JM, Larruskain J, Alonso M, Ercibengoa M. Antimicrobial susceptibilities and serotypes of Streptococcus pneumoniae isolates from elderly patients with pneumonia and acute exacerbation of chronic obstructive pulmonary disease.Antimicrob Agents Chemother. 2011;55(6):2729-34. DOI: 10.1128/AAC.01546-10 PMID: 21402843
27. Kronenberg A, Koenig S, Droz S, Mühlemann K. Active surveillance of antibiotic resistance prevalence in urinary tract and skin infections in the outpatient setting.Clin Microbiol Infect. 2011;17(12):1845-51. DOI: 10.1111/j.1469-0691.2011.03519.x PMID: 21880098
28. Plüss-Suard C, Pannatier A, Kronenberg A, Mühlemann K, Zanetti G. Hospital antibiotic consumption in Switzerland: comparison of a multicultural country with Europe.J Hosp Infect. 2011;79(2):166-71. DOI: 10.1016/j.jhin.2011.05.028 PMID: 21820207
29. Achermann R, Suter K, Kronenberg A, Gyger P, Mühlemann K, Zimmerli W, et al. Antibiotic use in adult outpatients in Switzerland in relation to regions, seasonality and point of care tests. Clin Microbiol Infect. 2011;17(6):855-61. DOI: 10.1111/j.1469-0691.2010.03348.x PMID: 20731682